To validate the sensitizing effect of KEAP1 mutation or deficiency on AURKA inhibitors, we initially analyzed the sensitivity of NSCLC cell lines with wildtype or mutant KEAP1 to AURKA inhibitors in the Cancer Drug Sensitivity Genomics database GDSC. The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.